This page uses content from Wikipedia and is licensed under CC BY-SA.
Rimostil (developmental code name P-081) is a dietary supplement and extract of isoflavones from red clover which was under development by Kazia Therapeutics (formerly Novogen) for the prevention of postmenopausal osteoporosis and cardiovascular disease and for the treatment of menopausal symptoms and hyperlipidemia but was never approved for medical use.     It is enriched with isoflavone  phytoestrogens such as formononetin, biochanin A, daidzein, and genistein, and is proposed to act as a selective estrogen receptor modulator, with both estrogenic and antiestrogenic effects in different tissues.   The extract reached  phase II clinical trials for cardiovascular disorders, hyperlipidemia, and postmenopausal osteoporosis prior to the discontinuation of its development in 2007.
^ a b
Cho CH, Nuttall ME (April 2001). "Therapeutic potential of oestrogen receptor ligands in development for osteoporosis". Expert Opin Emerg Drugs. 6 (1): 137–54. doi: 10.1517/14728188.8.131.52. PMID 15989501.
^ a b
Ososki AL, Kennelly EJ (September 2003). "Phytoestrogens: a review of the present state of research". Phytother Res. 17 (8): 845–69. doi: 10.1002/ptr.1364. PMID 13680814.
^ a b
Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T (2001). "The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism". Menopause. 8 (4): 259–65. doi: 10.1097/00042192-200107000-00007. PMID 11449083.
^ a b
Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR (July 2003). "Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial". JAMA. 290 (2): 207–14. doi: 10.1001/jama.290.2.207. PMID 12851275.